04 · Five things to know · 03

Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Must read

What happened

Actinogen said on 11.19 that XanaMIA, a randomized, double-blind, placebo-controlled Phase 2b/3 trial of Xanamem (emestedastat), an oral 11β-HSD1 inhibitor, in 247 people with mild to moderate Alzheimer’s disease and raised pTau181, missed its primary endpoint. The mean benefit on CDR-SB at week 36 was 0.10 points versus placebo (p = 0.65), which the company calls “numerically, but not statistically superior.” In a prespecified subgroup above the median age of 75, 40% versus 22% showed no progression on CDR-SB (p = 0.02), while the mean slowing of 0.39 points was not significant (p = 0.22). The company reports no drug-related serious adverse events and plans talks with FDA and partners on a path in older patients. Claim

Why it matters

A subgroup result after a missed primary can point to the next trial but cannot carry this one. Analysis

What we’re watching

What FDA says about the older-patient path, and the open-label extension results the company plans to present at a future scientific meeting.

Claim CheckMatch

CLAIM CHECK

Match NCT06125951 registers CDR-SB change at 36 weeks as its efficacy primary, with adverse events as a second primary, and 247 enrolled; the release reports that measure. The age subgroup is not a registered primary.

Sources

Also in Five things to know

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Five things to know